29 May 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

Issue of Equity

Coiled Therapeutics (AIM: COIL, OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces the issue of 934,783 new ordinary shares of one pence each ("New Ordinary Shares") in settlement of amounts owing to a consultant (434,783 New Ordinary Shares) and a vendor (500,000 New Ordinary Shares). The issue of the New Ordinary Shares is conditional on Admission (defined below).

Admission and Total Voting Rights

Application will be made for the New Ordinary Shares to be admitted to trading on AIM, which is expected to occur on or around 3 June 2026 ("Admission"). The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares of one pence each ("Ordinary Shares") traded on AIM.

Following Admission, the Company's issued share capital will comprise 426,791,322 Ordinary Shares, with each share carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury. The figure of 426,791,322 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or of a change to their interest in the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Enquiries:

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL, OTCQB: COTXF) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884).  Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments.   The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.

By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, addressing a significant unmet medical need for the treatment of brain metastases.

The asset is currently in an ongoing Phase I open-label dose-escalation study and early clinical signals have shown encouraging anti-tumour activity and a benign safety profile, with the Company planning to initiate dose expansion cohorts in lead indications, including prostate and ovarian cancer, during 2026.

For more information, please visit: www.coiledplc.com